

Research Questions

Why does this develop?

How do people have immunity pre-vaccine?

What are the mechanisms? What are the subtypes? Why do some people evolve to CVID?

Additional/upgraded vaccines?

Molecular Mimicry?

49

Research Questions

- ☐ Why does this develop?
- ☐ How do people have immunity pre-vaccine?
- ☐ What are the mechanisms? What are the subtypes? Why do some people evolve to CVID?
- ☐ Additional/upgraded vaccines?
- ☐ Molecular Mimicry?

Clinical Update: Ig Replacement

TABLE XIII. Currently available immunoglobulin products and their properties

Route/product	Dosage formulation	Diluent	Refrigeration required?	Filtration required?	Osmolality (mOsm/L)	Sodium	pH	IgA (μg/mL)	Stabilizer or regulator	Pathogen inactivation/removal*
IV										
Bivigam	10% Liquid	NA	Yes	No	Not Available	0.100-0.140 mol/L	4.0-4.6	≤200	Glycine	FP, S/D, NF
Carimune NF	Lyophilized	0.9% sodium chloride, sterile water, 5% dextrose	No	No	498 (3%), 690 (6%), 882 (9%), 1074 (12%)	0.01 mEq/mL (3%), 0.02 (6%), 0.03 (9%), 0.041 (12%)	6.6	720	Sucrose	DF, pH 4, pH 4/pepsin, NF
					192 (3%), 384 (6%), 576 (9%), 768 (12%)	None				
					444 (3%), 636 (6%), 828 (9%), 1020 (12%)	None				

Guiding principle issue
Indication of immunoglobulin therapy
Diagnoses
Frequency of immunoglobulin treatment
Dose
IgG trough levels
Site of care
Route
Product

Perez et al. Update on the use of immunoglobulin in human disease: A review of evidence *JACI* 139 (3) 2017.